Core Scientific, Inc.
CORZQ
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -49.51% | -8.82% | 1.77% | 29.62% | -36.40% |
| Total Other Revenue | -28.77% | -17.96% | 14.07% | 52.98% | 50.65% |
| Total Revenue | -33.12% | -15.54% | 11.18% | 48.60% | 17.05% |
| Cost of Revenue | -16.34% | -6.98% | 10.27% | 14.37% | -39.09% |
| Gross Profit | -76.94% | -69.67% | 13.40% | 144.32% | 183.19% |
| SG&A Expenses | 52.46% | 72.45% | 26.79% | -33.58% | -27.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -79.49% | -35.22% | 472.96% | 21,037.50% | 2,553.13% |
| Total Operating Expenses | -1.46% | 9.19% | 14.94% | 6.36% | -34.87% |
| Operating Income | -837.24% | -247.83% | -34.55% | 676.73% | 106.08% |
| Income Before Tax | -35.73% | -1,009.20% | -8,713.40% | 74,359.51% | 57.19% |
| Income Tax Expenses | 11.61% | 17.54% | 11.63% | 98.08% | 101.56% |
| Earnings from Continuing Operations | -35.69% | -1,006.45% | -8,592.18% | 54,401.80% | 55.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.69% | -1,006.45% | -8,592.18% | 54,401.80% | 55.00% |
| EBIT | -837.24% | -247.83% | -34.55% | 676.73% | 106.08% |
| EBITDA | -137.16% | -195.93% | 18.83% | 217.89% | 285.85% |
| EPS Basic | -18.77% | -991.26% | -18,229.67% | 91,330.00% | 52.31% |
| Normalized Basic EPS | -313.23% | -4,544.98% | -17,936.71% | 1,497.71% | 21.95% |
| EPS Diluted | -17.78% | -967.45% | -18,233.33% | 77,640.00% | 51.91% |
| Normalized Diluted EPS | -313.23% | -4,544.98% | -17,936.71% | 1,206.29% | 21.95% |
| Average Basic Shares Outstanding | -20.50% | -23.53% | -52.50% | -38.48% | -5.64% |
| Average Diluted Shares Outstanding | -20.50% | -23.53% | -52.50% | -24.74% | -5.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
